Adagio Medical Holdings, Inc. 8-K

What Happened

• Adagio Medical Holdings, Inc. (ADGM) announced on April 8, 2026 (Current Report on Form 8-K) that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to investigate its next‑generation vCLAS™ Ventricular Ablation System. The company attached a press release announcing the IDE approval as Exhibit 99.1 to the 8‑K.

Key Details

• Date filed: April 8, 2026 (Form 8‑K, Item 8.01 — Other Events).
• Regulatory action: FDA granted IDE approval to allow clinical investigation of the vCLAS ventricular ablation system.
• Disclosure: Press release titled “Adagio Medical Receives IDE Approval from the FDA to Investigate the Next-Generation vCLAS™ Ventricular Ablation System” included as Exhibit 99.1.

Why It Matters

• An IDE approval lets Adagio begin or expand clinical studies in the U.S. to collect safety and effectiveness data under FDA oversight, a key step toward potential future marketing authorization.
• For investors, IDE clearance is a regulatory milestone that can validate the technology and advance the company’s clinical and regulatory pathway; the filing does not include financial results or timelines.